Clinical data for Episealer® accepted for podium presentation at German scientific congress
Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract “Patient specific mini-metal implants. The future of cartilage repair for the right patient” by Dr. med. J. Holz et al. has been accepted for a podium presentation at the 13th annual Endoprothetikkongress (arthroplasty congress) in Berlin, Germany, which will take place on February 13-15, 2020.
The abstract focuses on clinical outcomes for patients in the “gap age”, 35-60 years old, that have undergone treatment of focal symptomatic chondral defects using the knee implant Episealer®. The abstract shows excellent early clinical results from the treatment of cartilage lesions on the femoral condyles and the trochlea area of the knee with an individualised implant.
“This is very positive, and we can once again conclude that the interest in the Episealer® technology is increasing. Strong clinical results in combination with a challenging clinical problem generate an increasing level of interest. Germany is currently our most important market, and additional presentations at clinical congresses are important for us” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.